In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

By placing the cells on surfaces patterned with fractal shapes that mimic natural structures in the kidney, the team ...

Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is associated with increased morbidity and mortality. The pathogenesis of LN involves complex immune-mediated ...

Although the pathophysiology of mesangial cells has long been considered to be the major factor in the development of glomerulosclerosis in type 1 or type 2 diabetes, more recent evidence suggests ...